Boehringer Ingelheim
Last updated Jul 24, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
76%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- HER2 Alterations
- Metabolic Disorders
- Oral Therapy
- Combination Therapy
Highest priority development: FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Regulatory precedent
Why this matters: sets a approval precedent in the same sub-indication (her2) as Boehringer Ingelheim.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 76%
Active Signals
12
Investigate Priority
0
Opportunity Score
889
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJul 24, 2026Score 75Boehringer Ingelheim's Zongertinib Trial Targets Advanced Cancers with HER2 Alterations
Oncology · HER2 Alterations
- MonitorJul 15, 2026Score 75Boehringer Ingelheim Study on HER2-Altered Metastatic Breast Cancer Treatment Patterns
Oncology · Breast Cancer
- MonitorJun 25, 2026Score 75Boehringer Ingelheim's Survodutide Trial for NASH/MASH with Cirrhosis Underway
Hepatology · NASH/MASH
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumorsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Ongoing | Cancer Accelerated ApprovalsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Verified Clinical Benefit | Cancer Accelerated ApprovalsLow Confidence · 54%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancerHigh Confidence · 92%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Boehringer Ingelheim right now?
- Which regulatory precedents should Boehringer Ingelheim monitor in Oncology and HER2 Alterations?
- Which pipeline programs should Boehringer Ingelheim prioritize for competitive review?
- What signals require immediate investigation for Boehringer Ingelheim?
- Summarize the strategic implications of recent developments for Boehringer Ingelheim.
- Where is the greatest uncertainty in Boehringer Ingelheim's competitive positioning?